Hongbo Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongbo Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Feng Chen
Department of Lung Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
5 shared publicationsWeipeng Shao
Department of Lung Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
5 shared publicationsBobo Li
Department of Thoracic Surgical Ward II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3 shared publicationsChengwei Zhao
Department of Lung Surgical, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3 shared publicationsHui Li
Department of Thoracic Surgical Ward II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3 shared publications- Hui Zhu
Shandong First Medical University and Shandong Academy of Medical Sciences
3 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Development and validation of a preoperative interpretable machine learning model for predicting myocardial injury following lung cancer surgery
- 4 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessDevelopment and validation of a preoperative interpretable machine learning model for predicting myocardial injury following lung cancer surgery
- 18 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5421-5422
ASO Author Reflections: Unmasking the Silent Threat: Myocardial Injury After Lung Cancer Surgery and Its Link to Major Adverse Cardiovascular Events
- 18 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5421-5422
ASO Author Reflections: Unmasking the Silent Threat: Myocardial Injury After Lung Cancer Surgery and Its Link to Major Adverse Cardiovascular Events
- 5 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5399-5409
Myocardial Injury After Lung Cancer Surgery: Incidence, Characteristics, Risk Factors, and Prognosis: A Retrospective Cohort Study
This study aimed to investigate the incidence, characteristics, risk factors, and prognostic implications of myocardial injury after non-cardiac surgery (M
- 5 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5399-5409
Myocardial Injury After Lung Cancer Surgery: Incidence, Characteristics, Risk Factors, and Prognosis: A Retrospective Cohort Study
This study aimed to investigate the incidence, characteristics, risk factors, and prognostic implications of myocardial injury after non-cardiac surgery (M
- Open Access
- 13 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1623248
Deep learning radiomics model of epicardial adipose tissue for predicting postoperative atrial fibrillation after lung lobectomy in lung cancer patients
Objective: To develop and validate a deep learning (DL) radiomics model based on epicardial adipose tissue (EAT) for identifying high-risk lung cancer patients with postoperative atrial fibrillation after lung lobectomy.Methods: A total of 1,008 patients from two centers were included. Handcrafted and DL radiomics features were extracted from the preoperative contrast-enhanced chest CT images of EAT. Clinical features and handcrafted and DL radiomics signatures were integrated to construct predictive models using the logistic regression algorithm as the baseline model. Twenty DL radiomics models were constructed through various combinations of machine learning algorithms and resampling techniques. The post hoc Nemenyi test was employed to compare the predictive performance in terms of the area under the receiver operating characteristic curve (AUC), G-mean, and F-measure.Results: Advanced age and male sex were identified as independent risk factors for POAF. The DL radiomics model, integrating clinical features, handcrafted radiomics signature, and DL radiomics signature, outperformed the clinical model, achieving AUC values of 0.890 (95% CI: 0.816–0.963), 0.876 (95% CI: 0.755–0.997), and 0.803 (95% CI: 0.651–0.955) in the training, testing, and validation cohorts, respectively. The results of the post hoc Nemenyi tests indicated that neither machine learning algorithms nor resampling techniques significantly improved model performance, as measured by the AUC, G-mean, or F-measure.Conclusion: The DL radiomics model based on preoperative EAT images effectively identifies high-risk lung cancer patients with POAF following lung lobectomy and offers a novel tool for risk stratification.
- 13 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1623248
Open AccessDeep learning radiomics model of epicardial adipose tissue for predicting postoperative atrial fibrillation after lung lobectomy in lung cancer patients
Objective: To develop and validate a deep learning (DL) radiomics model based on epicardial adipose tissue (EAT) for identifying high-risk lung cancer patients with postoperative atrial fibrillation after lung lobectomy.Methods: A total of 1,008 patients from two centers were included. Handcrafted and DL radiomics features were extracted from the preoperative contrast-enhanced chest CT images of EAT. Clinical features and handcrafted and DL radiomics signatures were integrated to construct predictive models using the logistic regression algorithm as the baseline model. Twenty DL radiomics models were constructed through various combinations of machine learning algorithms and resampling techniques. The post hoc Nemenyi test was employed to compare the predictive performance in terms of the area under the receiver operating characteristic curve (AUC), G-mean, and F-measure.Results: Advanced age and male sex were identified as independent risk factors for POAF. The DL radiomics model, integrating clinical features, handcrafted radiomics signature, and DL radiomics signature, outperformed the clinical model, achieving AUC values of 0.890 (95% CI: 0.816–0.963), 0.876 (95% CI: 0.755–0.997), and 0.803 (95% CI: 0.651–0.955) in the training, testing, and validation cohorts, respectively. The results of the post hoc Nemenyi tests indicated that neither machine learning algorithms nor resampling techniques significantly improved model performance, as measured by the AUC, G-mean, or F-measure.Conclusion: The DL radiomics model based on preoperative EAT images effectively identifies high-risk lung cancer patients with POAF following lung lobectomy and offers a novel tool for risk stratification.
- Open Access
- 26 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Clinical outcomes of conversion surgery following neoadjuvant chemoimmunotherapy in potentially resectable stage IIIA/IIIB non-small cell lung
Neoadjuvant chemoimmunotherapy has been successfully used in patients with resectable non-small-cell lung cancer (NSCLC). However, its application to potentially resectable IIIA/IIIB NSCLC remains controversial. This retrospective study aims to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy followed by conversion surgery in patients with potentially resectable stage III NSCLC, focusing on conversion rate and survival benefits. Patients with ‘potentially resectable’ stage IIIA/IIIB NSCLC who were deemed unsuitable for complete (R0) resection at initial diagnosis were retrospectively identified. After 2–4 cycles of treatment, all patients were reevaluated for surgical resectability. Data on patient characteristics, radiological and pathological responses, and survival outcomes were collected. In total, 148 patients were included in the final analysis. Upon the completion of neoadjuvant therapy, 105 patients were considered suitable for conversion surgery. Three patients refused surgery, and 102 patients ultimately underwent surgery, yielding a conversion rate of 70.9% and a resection rate of 68.9%. The rate of complete (R0) resection was 100%, with a major pathological response (MPR) of 64.7% and a pathologic complete response (pCR) of 41.2%. Postoperative complications were observed in nine patients (8.8%), and there was no surgery-related mortality within 30 days. The median progression-free survival (PFS) was 19.1 months in the non-surgery group, and the overall survival (OS) was not reached. In the 102 patients who underwent conversion surgery, both the median PFS and OS were not reached, accompanied by 2-year OS and PFS rates of 87.3% and 78.4%, respectively. Our findings showed that neoadjuvant chemoimmunotherapy expanded the opportunities for conversion surgery in potentially resectable cases. Subsequent conversion surgery is safe and has the potential for significant survival benefits.
- 26 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessClinical outcomes of conversion surgery following neoadjuvant chemoimmunotherapy in potentially resectable stage IIIA/IIIB non-small cell lung
Neoadjuvant chemoimmunotherapy has been successfully used in patients with resectable non-small-cell lung cancer (NSCLC). However, its application to potentially resectable IIIA/IIIB NSCLC remains controversial. This retrospective study aims to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy followed by conversion surgery in patients with potentially resectable stage III NSCLC, focusing on conversion rate and survival benefits. Patients with ‘potentially resectable’ stage IIIA/IIIB NSCLC who were deemed unsuitable for complete (R0) resection at initial diagnosis were retrospectively identified. After 2–4 cycles of treatment, all patients were reevaluated for surgical resectability. Data on patient characteristics, radiological and pathological responses, and survival outcomes were collected. In total, 148 patients were included in the final analysis. Upon the completion of neoadjuvant therapy, 105 patients were considered suitable for conversion surgery. Three patients refused surgery, and 102 patients ultimately underwent surgery, yielding a conversion rate of 70.9% and a resection rate of 68.9%. The rate of complete (R0) resection was 100%, with a major pathological response (MPR) of 64.7% and a pathologic complete response (pCR) of 41.2%. Postoperative complications were observed in nine patients (8.8%), and there was no surgery-related mortality within 30 days. The median progression-free survival (PFS) was 19.1 months in the non-surgery group, and the overall survival (OS) was not reached. In the 102 patients who underwent conversion surgery, both the median PFS and OS were not reached, accompanied by 2-year OS and PFS rates of 87.3% and 78.4%, respectively. Our findings showed that neoadjuvant chemoimmunotherapy expanded the opportunities for conversion surgery in potentially resectable cases. Subsequent conversion surgery is safe and has the potential for significant survival benefits.
- Open Access
- 25 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (4) , 1-13
Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
Objective Despite the promising potential of neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC), there is limited consensus on the optimal treatment strategy for potentially resectable NSCLC. This study aimed to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy (neoCT/IO) with planned surgery versus definitive concurrent chemoradiation followed by immunotherapy (cCRT + IO) in potentially resectable stage III NSCLC. Methods This retrospective study analyzed data from patients with potentially resectable stage III NSCLC who underwent neoCT/IO with planned surgery or cCRT + IO between March 2020 and June 2023. Propensity score matching (PSM) was used to balance heterogeneity between groups. Efficacy outcomes, safety profiles and patterns of disease recurrence were assessed. Results A total of 308 eligible patients were included in this study, of whom 195 (63.3%) underwent neoCT/IO and 113 (36.7%) received cCRT + IO. The neoCT/IO group consisted of patients who underwent neoCT/IO + Surgery and neoCT/IO + Radiotherapy. After 1:1 PSM, each group consisted of 105 patients. The median progression-free survival (PFS) was 25.9 months in the cCRT + IO group and not reached (NR) in the neoCT/IO group (hazard ratio: 2.91, 95% confidence interval: 1.77–4.78; p < 0.001). Median overall survival (OS) was NR in either group, with 3-year OS rates of 87.5% in the neoCT/IO group and 75.0% in the cCRT + IO group (p = 0.22). The incidence of grade 3/4 treatment-related adverse events was similar in both groups, except for a higher incidence of grade 3/4 hematological toxicity in the cCRT + IO group. Conclusions For patients with potentially resectable stage III NSCLC, neoCT/IO appears to be a safe approach and may offer better survival outcomes compared with cCRT + IO. Prospective randomized trials are needed to further validate these findings.
- 25 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (4) , 1-13
Open AccessComparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
Objective Despite the promising potential of neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC), there is limited consensus on the optimal treatment strategy for potentially resectable NSCLC. This study aimed to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy (neoCT/IO) with planned surgery versus definitive concurrent chemoradiation followed by immunotherapy (cCRT + IO) in potentially resectable stage III NSCLC. Methods This retrospective study analyzed data from patients with potentially resectable stage III NSCLC who underwent neoCT/IO with planned surgery or cCRT + IO between March 2020 and June 2023. Propensity score matching (PSM) was used to balance heterogeneity between groups. Efficacy outcomes, safety profiles and patterns of disease recurrence were assessed. Results A total of 308 eligible patients were included in this study, of whom 195 (63.3%) underwent neoCT/IO and 113 (36.7%) received cCRT + IO. The neoCT/IO group consisted of patients who underwent neoCT/IO + Surgery and neoCT/IO + Radiotherapy. After 1:1 PSM, each group consisted of 105 patients. The median progression-free survival (PFS) was 25.9 months in the cCRT + IO group and not reached (NR) in the neoCT/IO group (hazard ratio: 2.91, 95% confidence interval: 1.77–4.78; p < 0.001). Median overall survival (OS) was NR in either group, with 3-year OS rates of 87.5% in the neoCT/IO group and 75.0% in the cCRT + IO group (p = 0.22). The incidence of grade 3/4 treatment-related adverse events was similar in both groups, except for a higher incidence of grade 3/4 hematological toxicity in the cCRT + IO group. Conclusions For patients with potentially resectable stage III NSCLC, neoCT/IO appears to be a safe approach and may offer better survival outcomes compared with cCRT + IO. Prospective randomized trials are needed to further validate these findings.
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (10) , 6427-6440
Pathological responses of primary tumor and lymph nodes in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: a retrospective real-world study
Background: In patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy (NCIT), inconsistent pathological responses between the tumor and lymph nodes (LNs) are often observed. There has been limited evidence comparing the different responses of tumors and LNs in those patients. This retrospective real-world analysis intended to evaluate the clinical and pathological response of primary tumors and LNs, and the long-term outcomes in NSCLC patients after NCIT. Methods: We included resectable NSCLC patients who had received neoadjuvant therapy and had available clinicopathological records. The progression-free survival (PFS) and overall survival (OS) outcomes were analyzed using survival analysis. Results: In total, 204 patients were included in the final analysis. Patients were predominantly male (85.8%) and ever-smokers (66.2%), with a median age of 63 years. No significant difference was observed in intraoperative bleeding (P=0.51 and P=0.54) and operation time (P=0.57 and P=0.58) between the major pathologic response (MPR) and pathological complete response (pCR) group, respectively. Patients who were male (pCR, P=0.01; MPR, P=0.004), with squamous cell carcinoma (SCC) (pCR, P=0.02; MPR, P=0.001), and overall response rate (ORR) (pCR, PConclusions: In this real-world study, the combination of tumor and LNs responses was significantly associated with prognosis, and we demonstrated that ypTMPR(+)/ypN(0) group had a better prognosis, followed by ypTMPR(−)/ypN(0), ypTMPR(+)/ypN(0), and ypTMPR(−)/ypN(1+2). We advocate for ypTMPR(+)/ypN(0) status as a better surrogate of PFS in resectable NSCLC patients after NCIT.
- 1 October 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (10) , 6427-6440
Open AccessPathological responses of primary tumor and lymph nodes in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: a retrospective real-world study
Background: In patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy (NCIT), inconsistent pathological responses between the tumor and lymph nodes (LNs) are often observed. There has been limited evidence comparing the different responses of tumors and LNs in those patients. This retrospective real-world analysis intended to evaluate the clinical and pathological response of primary tumors and LNs, and the long-term outcomes in NSCLC patients after NCIT. Methods: We included resectable NSCLC patients who had received neoadjuvant therapy and had available clinicopathological records. The progression-free survival (PFS) and overall survival (OS) outcomes were analyzed using survival analysis. Results: In total, 204 patients were included in the final analysis. Patients were predominantly male (85.8%) and ever-smokers (66.2%), with a median age of 63 years. No significant difference was observed in intraoperative bleeding (P=0.51 and P=0.54) and operation time (P=0.57 and P=0.58) between the major pathologic response (MPR) and pathological complete response (pCR) group, respectively. Patients who were male (pCR, P=0.01; MPR, P=0.004), with squamous cell carcinoma (SCC) (pCR, P=0.02; MPR, P=0.001), and overall response rate (ORR) (pCR, PConclusions: In this real-world study, the combination of tumor and LNs responses was significantly associated with prognosis, and we demonstrated that ypTMPR(+)/ypN(0) group had a better prognosis, followed by ypTMPR(−)/ypN(0), ypTMPR(+)/ypN(0), and ypTMPR(−)/ypN(1+2). We advocate for ypTMPR(+)/ypN(0) status as a better surrogate of PFS in resectable NSCLC patients after NCIT.
- Open Access
- 16 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1349300
Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study
Background: This study aimed to assess the role and effect of neoadjuvant targeted therapy (TT) versus targeted combined with chemotherapy (TC) for resectable EGFR-mutant non–small cell lung cancer (NSCLC).Methods: Between March 2021 and June 2023, 20 patients with stage IA3-IIIB NSCLC were enrolled in the study. Eleven patients received EGFR-TKIs in the TT group, while nine patients received EGFR-TKIs and two cycles of cisplatin-based doublet chemotherapy (TC group). We compare the differences between the two groups through the following variables, including age, sex, surgical approach, postoperative complications, neoadjuvant therapy adverse events, complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), major pathologic response (MPR), and pathologic complete response (pCR).Results: Patients were predominantly female (75%) and never-smokers (95%). The average age was 59.2 years (range 46-79 years). Fifty-five percent harbored an exon 19 EGFR mutation and 45% an exon 21 mutation. The average targeted drug dosing time was 2.91 ± 1.7 (range 1-6) months in the TT group and 3.56 ± 3.54 (range 1-12) months in the TC group (P=0.598). The most common side effects were rash and diarrhea. No grade 5 events with neoadjuvant therapy were observed. The rate of R0 resection was 100% in all patients. Among the 11 patients in the TT group, 6 achieved a PR and 5 had SD, resulting in an ORR of 54.5%. Among the 9 patients in the TC group, 6 had PR and the remaining 3 had SD, resulting in an ORR of 66.6%. one patient (11.1%) in the TC group achieved pCR, while no patients in the TT group achieved pCR (P = 0.142). Two patients (18.2%) in the TT group reached MPR, and 2 patients (22.2%) in the TC group reached MPR (P = 0.257). The overall clinical downstage rate is 60%. Only 9 (45%) cases of yield clinical TNM (ycTNM) were consistent with yield pathologic TNM (ypTNM).Conclusion: Results from this retrospective controlled research indicate that the neoadjuvant TT group is likely to be more effective outcomes and has safer profile in patients with EGFR-positive NSCLC than the neoadjuvant TC group. However, our results need to be validated in a multicenter, large sample prospective study.
- 16 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1349300
Open AccessNeoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study
Background: This study aimed to assess the role and effect of neoadjuvant targeted therapy (TT) versus targeted combined with chemotherapy (TC) for resectable EGFR-mutant non–small cell lung cancer (NSCLC).Methods: Between March 2021 and June 2023, 20 patients with stage IA3-IIIB NSCLC were enrolled in the study. Eleven patients received EGFR-TKIs in the TT group, while nine patients received EGFR-TKIs and two cycles of cisplatin-based doublet chemotherapy (TC group). We compare the differences between the two groups through the following variables, including age, sex, surgical approach, postoperative complications, neoadjuvant therapy adverse events, complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), major pathologic response (MPR), and pathologic complete response (pCR).Results: Patients were predominantly female (75%) and never-smokers (95%). The average age was 59.2 years (range 46-79 years). Fifty-five percent harbored an exon 19 EGFR mutation and 45% an exon 21 mutation. The average targeted drug dosing time was 2.91 ± 1.7 (range 1-6) months in the TT group and 3.56 ± 3.54 (range 1-12) months in the TC group (P=0.598). The most common side effects were rash and diarrhea. No grade 5 events with neoadjuvant therapy were observed. The rate of R0 resection was 100% in all patients. Among the 11 patients in the TT group, 6 achieved a PR and 5 had SD, resulting in an ORR of 54.5%. Among the 9 patients in the TC group, 6 had PR and the remaining 3 had SD, resulting in an ORR of 66.6%. one patient (11.1%) in the TC group achieved pCR, while no patients in the TT group achieved pCR (P = 0.142). Two patients (18.2%) in the TT group reached MPR, and 2 patients (22.2%) in the TC group reached MPR (P = 0.257). The overall clinical downstage rate is 60%. Only 9 (45%) cases of yield clinical TNM (ycTNM) were consistent with yield pathologic TNM (ypTNM).Conclusion: Results from this retrospective controlled research indicate that the neoadjuvant TT group is likely to be more effective outcomes and has safer profile in patients with EGFR-positive NSCLC than the neoadjuvant TC group. However, our results need to be validated in a multicenter, large sample prospective study.
- Open Access
- 5 April 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Primary lung cancer in children and adolescents: Analysis of a surveillance, epidemiology, and end results database
Background: The incidence of primary lung cancer (LC) in children and adolescence was rare. We analyzed data from a SEER database to better define the incidence, clinical characters, pathology, treatment, and outcomes of rare primary malignant pulmonary tumors in childhood and adolescence.Methods: Patients were chosen from the SEER database (SEER*Stat 8.4.0 software) from 2000 to 2019 and all patients were pathologically diagnosed with primary malignant tumors of the lung and bronchus. Demographic characteristics of patients (age, gender, race, primary site, laterality, location, differentiation grade, operation methods, histology, and history of radiotherapy and chemotherapy), as well as TNM stage and survival time, were collected.Results: A total of 301 cases of children ≤19 years of age with a primary malignant pulmonary tumor were reported to the SEER database from 2000 to 2019. There were 143 men (47.5%) and 158 women (52.5%). Whites represented majority of patients (79.7%), followed by Black (13.6%) and others (6.7%). As for the primary site, the main site was the lower lobe (33.2%), followed by the upper lobe (26.9%). Most of the patients (80.4%) underwent surgery. Lobectomy (39.9%) is the main operation method. Only 28 (9.3%) patients received radiotherapy and 112 (37.2) patients received chemotherapy. Carcinoid tumor was the most common histology (29.6%), followed by pulmonary blastoma (PB) (22.3%), mucoepidermoid carcinoma (MEC) (12.3%), adenocarcinoma (10.3%), neuroendocrine tumor (NET) (5.7%), squamous cell carcinoma (SCC) (5.3%), atypical carcinoma (2.3%). The mean follow-up time was 100 months. For the entire group of children and adolescents, the 1-year OS was 89.1%, and the 3-year overall survival (OS) was 79.7%. the 5-year OS was 77.9%, the 10-year OS was 75.7%, and the 15-year OS was 73.9%. And 1-year lung cancer specificity survival (LCSS) was 89.8%, and the 3-year LCSS was 80.4%. the 5-year LCSS was 79.4%, the 10-year LCSS was 77.7%, and the 15-year LCSS was 75.9%. The OS of atypical carcinoma, carcinoid tumor, and MEC were in the top three.Conclusions: Primary LC in children and adolescent were rare and histopathological diverse. Fortunately, children and adolescents with LC had an overall favorable outcome after treatment. Histology, differentiation grade, surgery, TNM stage, and therapeutic modalities have important influence on OS. The further treatment experience of each pathological type would make better evidence-based practice possible.
- 5 April 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Open AccessPrimary lung cancer in children and adolescents: Analysis of a surveillance, epidemiology, and end results database
Background: The incidence of primary lung cancer (LC) in children and adolescence was rare. We analyzed data from a SEER database to better define the incidence, clinical characters, pathology, treatment, and outcomes of rare primary malignant pulmonary tumors in childhood and adolescence.Methods: Patients were chosen from the SEER database (SEER*Stat 8.4.0 software) from 2000 to 2019 and all patients were pathologically diagnosed with primary malignant tumors of the lung and bronchus. Demographic characteristics of patients (age, gender, race, primary site, laterality, location, differentiation grade, operation methods, histology, and history of radiotherapy and chemotherapy), as well as TNM stage and survival time, were collected.Results: A total of 301 cases of children ≤19 years of age with a primary malignant pulmonary tumor were reported to the SEER database from 2000 to 2019. There were 143 men (47.5%) and 158 women (52.5%). Whites represented majority of patients (79.7%), followed by Black (13.6%) and others (6.7%). As for the primary site, the main site was the lower lobe (33.2%), followed by the upper lobe (26.9%). Most of the patients (80.4%) underwent surgery. Lobectomy (39.9%) is the main operation method. Only 28 (9.3%) patients received radiotherapy and 112 (37.2) patients received chemotherapy. Carcinoid tumor was the most common histology (29.6%), followed by pulmonary blastoma (PB) (22.3%), mucoepidermoid carcinoma (MEC) (12.3%), adenocarcinoma (10.3%), neuroendocrine tumor (NET) (5.7%), squamous cell carcinoma (SCC) (5.3%), atypical carcinoma (2.3%). The mean follow-up time was 100 months. For the entire group of children and adolescents, the 1-year OS was 89.1%, and the 3-year overall survival (OS) was 79.7%. the 5-year OS was 77.9%, the 10-year OS was 75.7%, and the 15-year OS was 73.9%. And 1-year lung cancer specificity survival (LCSS) was 89.8%, and the 3-year LCSS was 80.4%. the 5-year LCSS was 79.4%, the 10-year LCSS was 77.7%, and the 15-year LCSS was 75.9%. The OS of atypical carcinoma, carcinoid tumor, and MEC were in the top three.Conclusions: Primary LC in children and adolescent were rare and histopathological diverse. Fortunately, children and adolescents with LC had an overall favorable outcome after treatment. Histology, differentiation grade, surgery, TNM stage, and therapeutic modalities have important influence on OS. The further treatment experience of each pathological type would make better evidence-based practice possible.
- Open Access
- 25 March 2020
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 17 (3) , 599-611
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
- 25 March 2020
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 17 (3) , 599-611
Open AccessThe mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients